Retrospective Non-interventional Study Evaluating Treatment Adaption During a One Year Follow-up After Completion of the 2-79-52030-207 Study in a Group of Acromegalic Patients With Macroadenoma Who Received 12 Injections of Lanreotide Autogel® 120 mg

Ipsen18 sites in 6 countries54 target enrollmentJanuary 2012

ConditionsAcromegaly

Overview

Phase: N/A
Intervention: Not specified
Conditions: Acromegaly
Sponsor: Ipsen
Enrollment: 54
Locations: 18
Primary Endpoint: Proportion of patients maintained on medical treatment with lanreotide Autogel
Status: Completed
Last Updated: 7 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

This non-interventional retrospective study aims to describe the therapeutic procedures and modalities received by patients and the correlation to hormone status, during a one year follow up from completion of the 2-79-52030-207 study.

Registry

clinicaltrials.gov

Start Date

January 2012

End Date

August 2013

Last Updated

7 years ago

Study Type

Observational

Sex

All

Investigators

Sponsor

Ipsen

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Completed the 2-79-52030-207 study and received 12 injections of lanreotide Autogel 120 mg, regardless of efficacy at the end of this period.
•Subject or in case of subject's death next of kin having given their written informed consent prior to collection of the data by the sponsor (if locally required)